6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	PIRSR-2023_05	PIRSR600732-5	320	397	1	C	396	396	LIPID: S-palmitoyl cysteine
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	C	118	118	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	F	366	366	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	Y	362	362	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	D	114	114	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	Y	115	115	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	W	339	339	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	W	110	110	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	A	202	202	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	S	203	203	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	M	346	346	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	L	199	199	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	E	206	206	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	W	370	370	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	A	190	190	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	A	119	119	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	T	343	343	putative ligand binding site
6FMnA0pf7c	17b56504c8f3c3780f4bbd063888109e	413	CDD-3.21	cd15296	48	391	17	Y	342	342	putative ligand binding site
lWYIhCDZyl	98a7060efa0ce7624b5df8cdbb1a0506	385	PIRSR-2023_05	PIRSR600732-5	295	375	1	C	370	370	LIPID: S-palmitoyl cysteine
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	D	94	94	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	S	179	179	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	Y	340	340	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	Y	95	95	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	L	175	175	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	Y	319	319	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	E	182	182	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	W	90	90	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	P	166	166	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	F	344	344	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	T	99	99	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	T	323	323	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	W	316	316	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	W	348	348	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	C	98	98	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	T	178	178	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	CDD-3.21	cd15295	16	374	17	S	320	320	putative ligand binding site
p5bEB7zEbb	c41889372e0438e6b305be543713f09d	390	PIRSR-2023_05	PIRSR600732-5	286	386	1	C	374	374	LIPID: S-palmitoyl cysteine
BCOck7IwQD	e27aebf1ef5674452097aec02eef0942	424	PIRSR-2023_05	PIRSR600732-5	338	415	1	C	413	413	LIPID: S-palmitoyl cysteine
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	F	414	414	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	C	139	139	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	Y	410	410	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	T	140	140	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	Y	136	136	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	A	223	223	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	D	135	135	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	W	131	131	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	W	387	387	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	M	394	394	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	W	418	418	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	T	391	391	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	L	220	220	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	Y	390	390	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	E	227	227	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	S	224	224	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	CDD-3.21	cd15296	56	439	17	V	211	211	putative ligand binding site
oBOfif9LBJ	33a42494f656f19aa53914c8ad9bbd5b	456	PIRSR-2023_05	PIRSR600732-5	369	448	1	C	444	444	LIPID: S-palmitoyl cysteine
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	PIRSR-2023_05	PIRSR600732-5	336	415	1	C	412	412	LIPID: S-palmitoyl cysteine
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	A	187	187	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	F	382	382	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	Y	378	378	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	L	196	196	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	W	355	355	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	E	203	203	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	S	200	200	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	M	362	362	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	C	115	115	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	W	386	386	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	T	116	116	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	Y	112	112	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	A	199	199	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	T	359	359	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	D	111	111	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	W	107	107	putative ligand binding site
QP7Akm5rRv	378bac8e0a19304a3bb05b0a915efb2d	429	CDD-3.21	cd15296	32	407	17	Y	358	358	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	PIRSR-2023_05	PIRSR600732-5	304	382	1	C	380	380	LIPID: S-palmitoyl cysteine
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	C	118	118	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	F	350	350	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	Y	346	346	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	D	114	114	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	Y	115	115	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	W	323	323	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	W	110	110	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	A	202	202	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	S	203	203	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	M	330	330	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	L	199	199	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	E	206	206	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	W	354	354	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	A	190	190	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	A	119	119	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	T	327	327	putative ligand binding site
E01291uRl2	7908208527756abb9ca16a1103d00874	407	CDD-3.21	cd15296	48	375	17	Y	326	326	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	M	370	370	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	C	118	118	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	W	394	394	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	D	114	114	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	T	367	367	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	Y	115	115	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	Y	366	366	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	W	110	110	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	A	202	202	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	S	203	203	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	L	199	199	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	F	390	390	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	E	206	206	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	Y	386	386	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	A	190	190	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	T	119	119	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	CDD-3.21	cd15296	35	415	17	W	363	363	putative ligand binding site
VYWJtTRjIz	c6c7e62bcd323a5ef51508d91fb2eab6	437	PIRSR-2023_05	PIRSR600732-5	332	423	1	C	420	420	LIPID: S-palmitoyl cysteine
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	S	195	195	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	L	191	191	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	W	388	388	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	E	198	198	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	A	182	182	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	Y	360	360	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	T	111	111	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	M	364	364	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	Y	380	380	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	C	110	110	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	T	361	361	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	D	106	106	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	W	357	357	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	Y	107	107	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	W	102	102	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	F	384	384	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	CDD-3.21	cd15296	27	409	17	A	194	194	putative ligand binding site
vyxoQRA4cI	b4e0bfad2fd4361f381f3986da7ef4e8	431	PIRSR-2023_05	PIRSR600732-5	339	415	1	C	414	414	LIPID: S-palmitoyl cysteine
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	PIRSR-2023_05	PIRSR600732-5	347	427	1	C	422	422	LIPID: S-palmitoyl cysteine
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	Y	388	388	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	L	208	208	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	E	215	215	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	T	369	369	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	S	212	212	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	W	365	365	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	C	127	127	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	F	392	392	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	T	128	128	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	Y	124	124	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	A	211	211	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	D	123	123	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	W	396	396	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	W	119	119	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	Y	368	368	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	A	199	199	putative ligand binding site
t5BNkjMP5g	41fd9edfa982b6085b0f9516711d8356	434	CDD-3.21	cd15296	44	417	17	M	372	372	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	PIRSR-2023_05	PIRSR600732-5	273	350	1	C	348	348	LIPID: S-palmitoyl cysteine
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	C	118	118	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	F	318	318	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	Y	314	314	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	D	114	114	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	Y	115	115	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	W	291	291	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	W	110	110	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	A	202	202	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	S	203	203	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	M	298	298	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	L	199	199	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	E	206	206	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	W	322	322	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	A	190	190	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	T	119	119	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	T	295	295	putative ligand binding site
HWHIYqt9D2	66d1edeb9ba7f9642a02775893d470db	373	CDD-3.21	cd15296	48	343	17	Y	294	294	putative ligand binding site
o5Gb2AX50s	32cc866d7635b8f884b80ff3744a8d6c	401	PIRSR-2023_05	PIRSR600732-5	298	392	1	C	386	386	LIPID: S-palmitoyl cysteine
o5Gb2AX50s	32cc866d7635b8f884b80ff3744a8d6c	401	PIRSR-2023_05	PIRSR600732-1	298	392	1	Q	343	343	BINDING: Zn(2+)
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	A	347	347	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	S	201	201	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	W	351	351	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	S	116	116	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	L	197	197	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	S	324	324	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	V	327	327	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	Y	323	323	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	A	117	117	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	F	113	113	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	W	108	108	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	Y	343	343	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	A	200	200	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	D	204	204	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	W	320	320	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	A	188	188	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	CDD-3.21	cd15048	47	372	17	D	112	112	putative ligand binding site
wuqkcc1DBy	80f3b7a64db0225a4a074d6ed6828b68	382	PIRSR-2023_05	PIRSR600732-1	301	371	1	Q	334	334	BINDING: Zn(2+)
WH8Pi4c3UY	73797d187d547940138a6b13d229bcf5	420	PIRSR-2023_05	PIRSR600732-5	329	405	1	C	405	405	LIPID: S-palmitoyl cysteine
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	PIRSR-2023_05	PIRSR600732-1	289	373	1	Q	322	322	BINDING: Zn(2+)
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	PIRSR-2023_05	PIRSR600732-5	289	373	1	C	363	363	LIPID: S-palmitoyl cysteine
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	I	311	311	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	W	84	84	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	C	92	92	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	N	160	160	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	T	172	172	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	F	333	333	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	T	314	314	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	D	88	88	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	S	173	173	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	W	307	307	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	Y	89	89	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	Y	329	329	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	E	176	176	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	W	337	337	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	Y	310	310	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	T	93	93	putative ligand binding site
n1WIkGjHMl	67fed1d4849a09117974475b5432fda8	384	CDD-3.21	cd15295	9	363	17	I	169	169	putative ligand binding site
OMGGNmbiRF	26fb457b9e625f964349b209f4a199e6	445	PIRSR-2023_05	PIRSR600732-5	353	429	1	C	428	428	LIPID: S-palmitoyl cysteine
WSkvfJAjT0	060da2cf18f5c2fd6b37c607fce0bac6	391	PIRSR-2023_05	PIRSR600732-5	285	390	1	C	376	376	LIPID: S-palmitoyl cysteine
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	Y	367	367	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	A	192	192	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	D	116	116	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	Y	117	117	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	M	371	371	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	Y	387	387	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	S	205	205	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	L	201	201	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	E	208	208	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	T	368	368	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	W	364	364	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	F	391	391	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	A	121	121	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	W	112	112	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	A	204	204	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	W	395	395	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	CDD-3.21	cd15296	37	416	17	C	120	120	putative ligand binding site
cOF5xGJ8FX	a4d7ad63d6f0067b1dd4433059779347	433	PIRSR-2023_05	PIRSR600732-5	345	425	1	C	421	421	LIPID: S-palmitoyl cysteine
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	PIRSR-2023_05	PIRSR600732-5	352	430	1	C	428	428	LIPID: S-palmitoyl cysteine
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	C	118	118	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	F	398	398	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	Y	394	394	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	D	114	114	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	Y	115	115	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	W	371	371	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	W	110	110	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	A	202	202	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	S	203	203	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	M	378	378	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	L	199	199	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	E	206	206	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	W	402	402	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	A	190	190	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	A	119	119	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	T	375	375	putative ligand binding site
RMNeZ2LTKq	052e8c632fd114cc4718cb9fdf950931	455	CDD-3.21	cd15296	48	423	17	Y	374	374	putative ligand binding site
u4wmYRSBXW	cb6efe7594ede0947c52d309463543d5	385	PIRSR-2023_05	PIRSR600732-1	297	376	1	Q	330	330	BINDING: Zn(2+)
u4wmYRSBXW	cb6efe7594ede0947c52d309463543d5	385	PIRSR-2023_05	PIRSR600732-5	297	376	1	C	373	373	LIPID: S-palmitoyl cysteine
